AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01945528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-guided tenotomy with PRP
Description: Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure
Study NCT02857114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: massage
Study NCT01941524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant alfa instillation
Description: aEEG and NIRS monitoring during poractant alfa instilation
Study NCT01941524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beractant instillation
Description: aEEG and NRs monitoring during beractant instillation
Study NCT01945528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-guided tenotomy with lidocaine
Description: Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
Study NCT01595607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Treatment
Description: Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
Study NCT01595607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Treatment
Description: Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
Study NCT02516046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq) IV single-dose
Study NCT02516046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: positron emission tomography (PET) scan
Study NCT01725711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPRA Implant System
Study NCT03546907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
Study NCT03736954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive suggestion
Description: humanization of critical care experience with positive reframing of hospital course on daily basis to eligible participants
Study NCT03546907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Any short-acting β agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
Study NCT01999855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phoniatric tests
Study NCT01999855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phoniatric tests
Study NCT05049837 — intervention group
Intervention type: OTHER
Intervention: Group Specific Aim 1
Description: 600 cases: two normal and two tumor formalin-fixed tissue samples
Study NCT03546907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any short-acting β agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
Study NCT05049837 — intervention group
Intervention type: OTHER
Intervention: Group Specific Aim 2
Description: 600 cases: two normal and two tumor formalin-fixed tissue samples.
Study NCT00983593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging
Description: 16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
Study NCT02137265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Clomiphene citrate 50 mg orally daily
Study NCT05049837 — intervention group
Intervention type: OTHER
Intervention: Group Specific Aim 3
Description: 600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples
Study NCT05049837 — intervention group
Intervention type: OTHER
Intervention: Group Specific Aim 4
Description: 600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
Study NCT02137265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill every other day
Study NCT00255125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soy Supplement
Description: Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
Study NCT00255125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
Study NCT05049837 — intervention group
Intervention type: OTHER
Intervention: Group Specific Aim 5
Description: 600 cases; two normal and two tumor formalin-fixed tissue samples
Study NCT05049837 — intervention group
Intervention type: OTHER
Intervention: Group Specific Aim 6
Description: 210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
Study NCT03427905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lipoaspiration
Description: Procedure: Lipoaspiration of fat and processing for the isolation of SVF Procedure: Transplantation
Study NCT03427905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation
Description: Procedure: Lipoaspiration of fat and processing for the isolation of SVF and culture for the obtention of ADSCS Procedure: Transplantation
Study NCT03150108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: 25 mcg rhPTH(1-84) SC injection
Study NCT04560855 — intervention group
Intervention type: DEVICE
Intervention: Connected devices measurements
Description: The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.
Study NCT03150108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: 50 mcg rhPTH(1-84) SC injection
Study NCT03150108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: 100 mcg rhPTH(1-84) SC injection
Study NCT02205606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0816 5mg
Description: P.O.
Study NCT02205606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0816 10mg
Description: P.O.
Study NCT02205606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0816 20mg
Description: P.O.
Study NCT03396848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHAReClinic
Description: Online clinic with educational modules
Study NCT04080258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh)
Description: The Osteopathic Manipulative Therapy includes both evaluation and treatment. The evaluation is semi-structured, two osteopaths will assess the presence of somatic dysfunctions which have to include the hyoid-pharyngeal, laryngeal, temporo-mandibular and lingual areas.~The therapy is based on the treatment of somatic dysfunctions with different approaches that include: the balanced ligamentous tension technique, the myofascial release, the visceral manipulation, and the balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 of evaluation and 30 of treatment.
Study NCT04080258 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch Therapy (LTT)
Description: The Light Touch Therapy is a sham treatment consistent with the OMTh one during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force.
Study NCT01790529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)
Study NCT01790529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
Study NCT03597100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cala TWO
Description: Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
Study NCT02620761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Description: Randomized to receive Fenoldopam or 0.9%NS
Study NCT02620761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%NS
Description: Randomized to receive Fenoldopam or 0.9%NS
Study NCT03696862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free gingival graft
Description: Use of free gingival graft to seal the socket after flapless atraumatic tooth extraction is performed, implant placement and filling the socket with bone graft.
Study NCT02640781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: self-expandable metal stent insertion(covered stent)
Description: Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
Study NCT02205606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306 5/10mg
Description: P.O.
Study NCT02205606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306 10/10mg
Description: P.O.
Study NCT02205606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306 20/10mg
Description: P.O.
Study NCT03180359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recommended vaccine scheme according to French Vaccine Schedule 2015
Description: * BCG~* Measles mumps rubella (MMR)~* Varicella (chicken pox)~* Rotavirus~* Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~* Yellow Fever~* Diphteria tetanus poliomyelitis whopping cough (DTwP)~* Haemophilus influenzae type b~* Hepatitis B~* Meningococcus conjugate~* Pneumococcus~* Human papillomavirus~* Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children
Study NCT01626911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous regional arterial infusion of low molecular weight heparin in celiac trunk
Description: Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
Study NCT01626911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General treatment
Description: Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
Study NCT01626911 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General treatment
Description: Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
Study NCT01123577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitor Group
Description: Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
Study NCT03535545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
Study NCT02594397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupoints combination 1
Study NCT02594397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupoints combination 2
Study NCT02594397 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupoints combination
Study NCT02172079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real mobilization-with-movement (MWM)
Study NCT02172079 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham mobilization-with-movement (MWM)
Study NCT00979446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided
Description: Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
Study NCT00979446 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed
Description: Received study materials but no phone coaching
Study NCT02575573 — intervention group
Intervention type: OTHER
Intervention: Factors influencing resuscitation decisions of patients
Study NCT02575573 — intervention group
Intervention type: OTHER
Intervention: Factors leading to not asking patients about resuscitation preference
Study NCT00832546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00832546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral NGX426 (Powder in solution)
Study NCT02529241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1:LCB01-0371
Description: 1. Period:LCB01-0371 Tablet 400 mg~2. Period: LCB01-0371 Tablet 400 mg
Study NCT02640781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: self-expandable metal stent insertion(uncovered stent)
Description: Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
Study NCT03737097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Spaced Education
Description: Investigators created a set of fall prevention strategies for multiple sclerosis patients into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), spaced education has been shown in randomized trials to improve knowledge acquisition, boosts learning retention for up to two years, and durably improves changes in behavior.
Study NCT03737097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure Education
Description: The investigators translated and validated the Minimizing Your Risk of Falls A GUIDE FOR PEOPLE WITH MS brochure developed by the National Multiple Sclerosis Society. The control cohort will receive the main education model for patients that has been used in the past few years.
Study NCT02027558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia treatment & PAP adherence
Description: Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
Study NCT02027558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General sleep education
Description: Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
Study NCT04783454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: educational video on training program design and healthy lifestyle 24 training sessions (12 on cardiovascular endurance training, 12 on mobility and strength)
Study NCT04676984 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Consultations
Description: The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
Study NCT02529241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2:LCB01-0371
Description: 1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg
Study NCT03627910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: symbiotic
Description: Feed supplementation
Study NCT00114244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT03535545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.
Study NCT00114244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00114244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02886221 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reverdin-Isham Osteotomy
Description: Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
Study NCT00203372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 and TAC
Description: Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
Study NCT00203372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Description: placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
Study NCT00203372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 and TAC
Description: one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
Study NCT00203372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 15 and TAC
Description: one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
Study NCT02695719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lubiprostone placebo-matching capsules
Study NCT01939808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Splint Neutral
Study NCT01939808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Splint Extended
Study NCT03655626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sepsis Watch
Description: The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
Study NCT02695719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone capsules
Study NCT03627910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc and arginine
Description: Feed supplementation